Leerink Partnrs Predicts Lower Earnings for Guardant Health

Guardant Health, Inc. (NASDAQ:GH - Free Report) - Analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of Guardant Health in a report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.76) per share for the quarter, down from their previous forecast of ($0.75). The consensus estimate for Guardant Health's current full-year earnings is ($2.90) per share. Leerink Partnrs also issued estimates for Guardant Health's Q4 2026 earnings at ($0.70) EPS and FY2027 earnings at ($2.13) EPS.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%.

A number of other equities analysts also recently commented on the company. Scotiabank lifted their price target on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Canaccord Genuity Group lifted their price target on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Mizuho started coverage on Guardant Health in a research report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price objective for the company. Stifel Nicolaus increased their target price on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, Raymond James reaffirmed an "outperform" rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $49.00.

Guardant Health Stock Down 1.7 %

Shares of GH stock traded down $0.81 on Wednesday, reaching $47.49. 834,290 shares of the stock were exchanged, compared to its average volume of 2,139,805. The stock has a market cap of $5.86 billion, a P/E ratio of -13.34 and a beta of 1.45. Guardant Health has a 1-year low of $17.52 and a 1-year high of $50.89. The firm has a 50 day moving average of $43.37 and a two-hundred day moving average of $37.42.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of Guardant Health in the 4th quarter worth approximately $26,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter valued at $43,000. Kimelman & Baird LLC acquired a new position in shares of Guardant Health during the 4th quarter worth approximately $58,000. NewEdge Advisors LLC boosted its holdings in shares of Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after acquiring an additional 230 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Guardant Health during the 4th quarter worth approximately $61,000. Hedge funds and other institutional investors own 92.60% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.